JAMA：“伟哥”可助抑郁女性找回激情
美国研究人员7月22日发表的一项研究报告称，治疗男性性功能障碍的药品“万艾可（俗称“伟哥”）同样能帮助患有抑郁症的女性找回激情。
性功能障碍是服用抗抑郁药物的常见副作用，也是许多人停用抗抑郁药物的主要原因。研究人员指出，收到抗抑郁药物处方的女性人数是男性的两倍，而万艾可目前却不被允许用于女性。
这份发表在最新一期《美国医学协会期刊》（JAMA）上的研究报告说，研究人员以98名女性为对象，她们的抑郁症状正在好转，却仍然患有性功能障碍。研究结果发现，万艾可在改善这些女性的性生活方面有效。
研究人员要求一半女性在性生活前一到两小时服用一粒万艾可，结果发现，这些女性中仅有28%的人报告性生活没有改善。另一半女性则服用了没有药效的安慰药，结果这些女性中大约73%的人报告性生活没有改善。
研究报告第一作者、新墨西哥大学医学院的乔治?尼恩贝格说，通过对抗抑郁药物的副作用给予治疗，女性抑郁症患者可以减少中途停用抗抑郁药物的几率，最终改善抑郁症治疗效果。（生物谷Bioon.com）
生物谷推荐原始出处：
JAMA，300(4):395-404，H. George Nurnberg，Susan Paine
Sildenafil Treatment of Women With Antidepressant-Associated Sexual Dysfunction
A Randomized Controlled Trial
JAMA. 2008;300(4):395-404.
Context Antidepressant-associated sexual dysfunction is a common adverse effect that frequently results in premature medication treatment discontinuation and for which no treatment has demonstrated efficacy in women.
Objective To evaluate the efficacy of sildenafil for sexual dysfunction associated with selective and nonselective serotonin reuptake inhibitors (SRIs) in women.
Design, Setting, and Participants An 8-week prospective, parallel-group, randomized, double-blind, placebo-controlled clinical trial conducted between September 1, 2003, and January 1, 2007, at 7 US research centers that included 98 previously sexually functioning, premenopausal women (mean [SD] age 37.1 [6] years) whose major depression was remitted by SRIs but who were also experiencing sexual dysfunction.
Intervention Forty-nine patients were randomly assigned to take sildenafil or placebo at a flexible dose starting at 50 mg adjustable to 100 mg before sexual activity.
Main Outcome Measures The primary outcome measure was the mean difference in change from baseline to study end (ie, lower ordinal score) on the Clinical Global Impression sexual function scale. Secondary measures included the Female Sexual Function Questionnaire, the Arizona Sexual Experience scale-female version, the University of New Mexico Sexual Function Inventory-female version, a sexual activity event log, and the Hamilton Depression Rating scale. Hormone levels were also assessed.
Results In an intention-to-treat analysis, women treated with sildenafil had a mean Clinical Global Impression–sexual function score of 1.9 (95% confidence interval [CI], 1.6-2.3) compared with those taking placebo (1.1; 95% CI, 0.8-1.5), with a mean end point difference of 0.8 (95% CI, 0.6-1.0; P = .001). Assigning baseline values carried forward to the 22% of patients who prematurely discontinued resulted in a mean end point in the sexual function score of 1.5 (95% CI, 1.1-1.9) among women taking sildenafil compared with 0.9 (95% CI, 0.6-1.3) among women taking placebo with a mean end point difference of 0.6 (95% CI, 0.3-0.8; P = .03). Baseline endocrine levels were within normal limits and did not differ between groups. The mean (SD) Hamilton scores for depression remained consistent with remission in both groups (4.0 [3.6]; P = .90). Headache, flushing, and dyspepsia were reported frequently during treatment, but no patients withdrew because of serious adverse effects.
Conclusion In this study population, sildenafil treatment of sexual dysfunction in women taking SRIs was associated with a reduction in adverse sexual effects.
- 众说风云 (已有0条评论)
